Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1541732 | 1.00 | MGLL (0.33) | MGLLGLA | |
| SCHEMBL9915235 | 0.83 | THRB (0.33) | MGLL | |
| SCHEMBL258692 | 0.82 | MGLL (0.36) | MGLLGLA | |
| SCHEMBL17430432 | 0.82 | MGLL (0.36) | MGLLGLA | |
| SCHEMBL733350 | 0.81 | MGLL (0.32) | MGLLGLA | |
| SCHEMBL12414055 | 0.80 | ALDH1A1 (0.33) | MGLL | |
| SCHEMBL13551294 | 0.80 | MGLL (0.35) | MGLLGLA | |
| SCHEMBL18908274 | 0.80 | MGLL (0.35) | MGLLGLA | |
| SCHEMBL493426 | 0.79 | MGLL (0.33) | MGLLGLA | |
| SCHEMBL3792332 | 0.79 | MGLL (0.33) | MGLLGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9731024-B2 | Nucleophilic catalysts for oxime linkage | BAXALTA INCORPORATED (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170157259-A1 | FACTOR VIII POLYMER CONJUGATES | BAXTER INTERNATIONAL INC. | 2017-06-08 | — | — | US | disclosed |
| US-20150024455-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-22 | — | — | US | disclosed |
| US-8809501-B2 | Nucleophilic catalysts for oxime linkage | BAXTER INTERNATIONAL INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8642737-B2 | Nucleophilic catalysts for oxime linkage | BAXTER INTERNATIONAL INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20140024808-A1 | FACTOR VIII POLYMER CONJUGATES | BAXTER HEALTHCARE SA (CH) | 2014-01-23 | — | — | US | disclosed |
| US-20130310546-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE AND USE OF NMR ANALYSES OF THE SAME | BAXALTA INCORPORATED | 2013-11-21 | — | — | US | disclosed |
| US-20130011900-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | BAXTER HEALTHCARE S.A. (CH) | 2013-01-10 | — | — | US | disclosed |
| US-20120329127-A1 | THERAPEUTIC PROTEINS WITH INCREASED HALF-LIFE AND METHODS OF PREPARING SAME | BAXTER HEALTHCARE S.A. (CH) | 2012-12-27 | — | — | US | disclosed |
| US-20120329127-A1 | THERAPEUTIC PROTEINS WITH INCREASED HALF-LIFE AND METHODS OF PREPARING SAME | BAXTER HEALTHCARE S.A. (CH) | 2012-12-27 | — | — | US | disclosed |
| US-7714114-B2 | Conjugates of an EPO moiety and a polymer | NEKTAR THERAPEUTICS (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100113364-A1 | FACTOR VIII POLYMER CONJUGATES | BAXTER HEALTHCARE S.A. (CH) | 2010-05-06 | — | — | US | disclosed |
| US-20100093934-A1 | PEGYLATION OF RECOMBINANT BLOOD COAGULATION FACTORS IN THE PRESENCE OF BOUND ANTIBODIES | BAXTER INTERNATIONAL INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-7683158-B2 | Pegylated factor VIII | BAXTER INTERNATIONAL INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS (US) | 2010-01-28 | — | — | US | disclosed |
| US-7645860-B2 | Factor VIII polymer conjugates | BAXTER HEALTHCARE S.A. (CH) | 2010-01-12 | — | — | US | disclosed |
| US-20090280550-A1 | Polymer-Factor IX Moiety Conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090247459-A1 | MODIFIED RECOMBINANT FACTOR VIII AND VON WILLEBRAND FACTOR AND METHODS OF USE | BAXTER INTERNATIONAL INC. | 2009-10-01 | — | — | US | disclosed |
| US-7579444-B2 | Polymer-factor IX moiety conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090076237-A1 | Factor VIII Polymer Conjugates | BAXTER HEALTHCARE S.A. (CH) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093934-A1 | PEGYLATION OF RECOMBINANT BLOOD COAGULATION FACTORS IN THE PRESENCE OF BOUND ANTIBODIES | F8, F13B, F13A1 | MGLL 835/4885GLA 108/4885 |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | MGLL 3641/4885GLA 333/4885 |
| US-20130011900-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | LPO, OGA, DAO | MGLL 3041/4885GLA 365/4885 |
| US-20170157259-A1 | FACTOR VIII POLYMER CONJUGATES | F8, F13B, F13A1 | MGLL 2776/4885GLA 223/4885 |
| US-20090247459-A1 | MODIFIED RECOMBINANT FACTOR VIII AND VON WILLEBRAND FACTOR AND METHODS OF USE | F8, F5, F13B | MGLL 3205/4885GLA 1722/4885 |
| US-20090076237-A1 | Factor VIII Polymer Conjugates | F8, F13B, F13A1 | MGLL 2776/4885GLA 223/4885 |
| US-20150024455-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | LPO, OGA, DAO | MGLL 3041/4885GLA 365/4885 |
| US-20130310546-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE AND USE OF NMR ANALYSES OF THE SAME | OGA, LPO, CA12 | MGLL 4007/4885GLA 597/4885 |
| US-20120329127-A1 | THERAPEUTIC PROTEINS WITH INCREASED HALF-LIFE AND METHODS OF PREPARING SAME | SERPINA6, FCGRT, ALB | MGLL 1997/4885GLA 762/4885 |
| US-20140024808-A1 | FACTOR VIII POLYMER CONJUGATES | F8, F13B, F13A1 | MGLL 2776/4885GLA 223/4885 |
| US-20100113364-A1 | FACTOR VIII POLYMER CONJUGATES | F8, F13B, F13A1 | MGLL 2776/4885GLA 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.